Edith Cowan University

Research Online
Research outputs 2022 to 2026
2022

A large-scale genome-wide cross-trait analysis reveals shared
genetic architecture between Alzheimer’s disease and
gastrointestinal tract disorders
Emmanuel O. Adewuyi
Edith Cowan University, e.adewuyi@ecu.edu.au

Eleanor K. O'Brien
Edith Cowan University, e.obrien@ecu.edu.au

Dale R. Nyholt
Tenielle Porter
Edith Cowan University, t.porter@ecu.edu.au

Simon Laws
Edith Cowan University, s.laws@ecu.edu.au

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Medicine and Health Sciences Commons
10.1038/s42003-022-03607-2
Adewuyi, E.O., O’Brien, E.K., Nyholt, D.R. et al. (2022). A large-scale genome-wide cross-trait analysis reveals shared
genetic architecture between Alzheimer’s disease and gastrointestinal tract disorders. Communications Biology, 5,
691.
https://doi.org/10.1038/s42003-022-03607-2
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/838

ARTICLE
https://doi.org/10.1038/s42003-022-03607-2

OPEN

A large-scale genome-wide cross-trait analysis
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tract disorders

1234567890():,;

Emmanuel O. Adewuyi
Simon M. Laws 1,2,4 ✉

1,2 ✉,

Eleanor K. O’Brien

1,2,

Dale R. Nyholt

3,

Tenielle Porter1,2,4 &

Consistent with the concept of the gut-brain phenomenon, observational studies suggest a
relationship between Alzheimer’s disease (AD) and gastrointestinal tract (GIT) disorders;
however, their underlying mechanisms remain unclear. Here, we analyse several genomewide association studies (GWAS) summary statistics (N = 34,652–456,327), to assess the
relationship of AD with GIT disorders. Findings reveal a positive signiﬁcant genetic overlap
and correlation between AD and gastroesophageal reﬂux disease (GERD), peptic ulcer
disease (PUD), gastritis-duodenitis, irritable bowel syndrome and diverticulosis, but
not inﬂammatory bowel disease. Cross-trait meta-analysis identiﬁes several loci
(Pmeta-analysis < 5 × 10−8) shared by AD and GIT disorders (GERD and PUD) including PDE4B,
BRINP3, ATG16L1, SEMA3F, HLA-DRA, SCARA3, MTSS2, PHB, and TOMM40. Colocalization and
gene-based analyses reinforce these loci. Pathway-based analyses demonstrate signiﬁcant
enrichment of lipid metabolism, autoimmunity, lipase inhibitors, PD-1 signalling, and statin
mechanisms, among others, for AD and GIT traits. Our ﬁndings provide genetic insights into
the gut-brain relationship, implicating shared but non-causal genetic susceptibility of GIT
disorders with AD’s risk. Genes and biological pathways identiﬁed are potential targets for
further investigation in AD, GIT disorders, and their comorbidity.
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lzheimer’s disease (AD) is the most prevalent form of
dementia, characterised by neurodegeneration and a
progressive decline in cognitive ability1,2. The disorder
ranks as a subject of increasing global public health importance
with consequences for wide-ranging social and economic adverse
impacts on sufferers, their families, and the society at large1. By
the year 2030, over 82 million people—and about 152 million by
2050—are projected to suffer from AD1,2. While AD has no
known curative treatments, and its pathogenesis is yet to be
clearly understood, a comprehensive assessment of its shared
genetics with other diseases (comorbidities) can provide a deeper
understanding of its underlying biological mechanisms and
enhance potential therapy development efforts.
Several studies have reported a pattern of co-occurrence of
dementia (and AD in particular) with certain gastrointestinal
tract (GIT) disorders, microbiota, dysbiosis or medications
commonly used in the treatment of peptic ulcer disease
(PUD)3–10. For example, an observational study reported more
than twice the odds of dementia in individuals with gastritis
(adjusted odds ratio [AOR]: 2.42, P < 0.001, 95% conﬁdence
interval [CI]: 1.68–3.49)3. Another observational study found a
signiﬁcant association between regular use of proton-pump
inhibitors (PPI, medications for gastritis duodenitis, gastroesophageal reﬂux disease [GERD] or PUD) and increased risk of
incident dementia (hazard ratio [HR]: 1.44 [95% CI, 1.36–1.52];
P < 0.001)4. Similarly, lansoprazole (a PPI) was reported to promote amyloid-beta (Aβ) production5, the accumulation of which
is central to one of the core hypotheses for the development of
AD11. More recently, a longitudinal study reported more than a
sixfold increased risk of AD in individuals with inﬂammatory
bowel disease (IBD) [HR: 6.19, 95%CI: 3.31–11.57], predicting
over ﬁve-fold increased incidence across all forms of dementia7.
The available evidence, thus, suggests comorbidity or some
forms of association between AD and GIT disorders, although it
is not clear whether GIT traits are risks for AD or vice versa.
Regardless, these ﬁndings agree with the concept of the
‘gut–brain’ axis or the ‘gastric mucosa–brain’ relationship, which
has been implicated between GIT-related traits and central nervous system (CNS) disorders including depression and Parkinson’s disease12–17. A relationship between AD and GIT disorders
or their comorbidity can worsen the quality of life of sufferers
while contributing to increased healthcare costs.
Despite the increasing number of studies reporting an association between AD and GIT traits, the biological mechanism(s)
underlying this potential association remains unclear. Moreover,
contrasting evidence exists7,18,19, leading to a longstanding debate
on the potential links of GIT traits to the risk of AD15,18–20.
Large-scale genome-wide association studies (GWAS), identifying
an increasing number of single nucleotide polymorphism (SNPs),
genes, and susceptibility loci, have been conducted separately for
AD and a range of GIT traits21–24. Findings from these GWAS
provide compelling evidence for the roles of genetics in the
aetiologies of AD and GIT disorders including GERD, PUD,
PGM (a combination of disease-diagnosis of PUD and/or GERD
and/or corresponding medications and treatments—a potential
proxy for PUD or GERD), gastritis-duodenitis, irritable bowel
syndrome (IBS), diverticular disease, and IBD21–24. However, to
the best of our knowledge, no study has leveraged the possible
pleiotropy between AD and GIT disorders as a basis for discovering their shared SNPs, genes and/or susceptibility loci.
In this study, we analyse well-powered GWAS summary data
to comprehensively assess the genetic relationship and potential
causal association between AD and GIT disorders. We demonstrate a positive signiﬁcant genetic overlap and correlation
between AD and GERD, PUD, PGM, IBS, gastritis-duodenitis,
and diverticular disease. Also, in a cross-trait GWAS meta2

analysis, we identify many loci shared by AD and GIT disorders.
Causality assessment reveals no evidence for a signiﬁcant causal
association between AD and GIT disorders. However, we identify
shared genes reaching genome-wide signiﬁcance for AD and GIT
disorders in gene-based association analyses. Lastly, pathwaybased analyses show signiﬁcant enrichment of lipid metabolism,
autoimmunity, lipase inhibitors, PD-1 signalling and statin
mechanisms, among others, for AD and GIT traits.
Results
Figure 1 presents a schematic workﬂow for this study. Brieﬂy, we
performed three broad levels of analyses—SNP-level, gene-level,
and pathway-based analyses. First, we used the linkage disequilibrium score regression (LDSC)25 to estimate the genetic
correlation between AD and GIT traits, and the ‘SNP effect
concordance analysis’ (SECA)26 method for concordance in SNP
risk effect assessment. Second, to identify SNPs and susceptibility
loci shared by AD and GIT disorders, we carried out GWAS
meta-analyses. We also applied the pairwise GWAS (colocalisation) method27 to identify independent genomic loci with shared
genetic inﬂuence on AD and GIT disorders. Third, using the
Mendelian randomisation (MR)28 and the Latent Causal Variable
(LCV)29 methods, we assessed potential (and partial) causal
associations between AD and GIT disorders. Lastly, we performed
gene and pathway-based analyses to identify shared genes
reaching genome-wide signiﬁcance and biological pathways for
AD and GIT disorders. The largest publicly available AD summary statistics and GIT summary data from research consortia or
public repositories were utilised for analysis (Table 1 and Supplementary Data 1).
Genetic correlation between AD and GIT disorders. We
assessed and quantiﬁed the SNP-level genetic correlation between
AD and GIT disorders using the LDSC25 analysis method. The
apolipoprotein E (APOE) region has a large effect on the risk of
AD; hence, we excluded APOE and the 500 kilobase (kb) ﬂanking
region (hg19, 19:44,909,039–45,912,650) from the AD GWAS.
We also excluded SNPs in the 26 to 36 megabase region of
chromosome six from the data given the complex LD structure in
the human major histocompatibility complex (MHC). Notably, in
analyses both with and without the APOE region, LDSC reveals a
signiﬁcant genetic correlation between AD and GIT traits
(Table 2). Genetic covariance intercept estimates were not signiﬁcantly different from zero (Supplementary Data 2), indicating
no sample overlap between our AD and GIT GWAS.
We found a positive and signiﬁcant genetic correlation (rg) of
AD (excluding APOE region) with GERD (rg = 0.25,
P = 8.19 × 10−18), PUD (rg = 0.28, P = 3.70 × 10−7), PGM (rg =
gastritis-duodenitis
(rg = 0.24,
0.22,
P = 2.38 × 10−14),
P = 2.40 × 10−8), IBS (rg = 0.19, P = 1.10 × 10−4), and diverticular disease (rg = 0.15, P = 2.97 × 10−5). However, we found no
evidence of a signiﬁcant genetic correlation between AD and IBD
(rg = 0.07, P = 9.94 × 10−2) [Table 2], which may be because of
the relatively small cases and sample size of the IBD GWAS
(Table 1 and Supplementary Data 1). Our estimates of effective
sample size (Supplementary Data 1) suggest the IBD GWAS was
underpowered compared to other GIT data sets. We reproduced a
pattern of a positive and signiﬁcant genetic correlation between
AD21 and the replication set of GIT traits with or without the
APOE region, except for IBD (Supplementary Data 3).
SNP effect concordance analysis (SECA) results. Using the
SECA method26, we assessed the directions of SNP-level genetic
overlap between AD and GIT disorders. We provide a more
comprehensive description of SECA in the methods section.
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Fig. 1 Study design and workﬂow: examining shared genetic and causality of GIT disorders with the risk of Alzheimer’s disease. GWAS genome-wide
association studies, SNP single-nucleotide polymorphism, SECA SNP effect concordance analysis, LDSC linkage disequilibrium score regression, LCV latent
causal variable, MAGMA multi-marker analysis of genomic annotation, MR Mendelian randomisation, MR-PRESSO Mendelian randomisation pleiotropy
residual sum and outlier, KEGG Kyoto Encyclopedia of Genes and Genomes.

Table 1 Summary of GWAS data sets analysed.
GWAS summary statistics

Cases

Control

Sample size

Ancestry

Phenotype source/deﬁnition

AD (Jansen et al.21)
GERD-UKBB_QSKIN (An et al.23)
PUD (Wu et al.22)
PGM (Wu et al.22)

71,880
71,522
16,666
90,175

383,378
261,079
439,661
366,152

455,258
332,601
456,327
456,327

European

Gastritis-duodenitis Phecode 535
(Lee Lab)
IBS (Wu et al.22)
Diverticulosis Phecode 562 (Lee Lab)
IBD (Wu et al.22)
Replication set
GORD (Wu et al.22)
PUD Phecode 531 (Lee Lab)
Lansoprazole (Watanabe et al.91)

28,941

378,124

407,065

Clinically diagnosed and UKB AD-by-proxy21
Data from the UKB and the QSKIN study23
UKB data code described in Wu et al.22,a
GWAS for diagnosis of PUD and/or GERD
and/or corresponding medications and
treatments from the UKB data22,a
Full European data subset from the Lee Lab

28,518
27,311
7045

426,803
334,783
449,282

455,321
362,094
456,327

UKB data code described in Wu et al.22,a
Full European data subset from the Lee Lab
UKB data code described in Wu et al.22,a

54,854
7436
13,559

401,473
401,525
266,884

456,327
408,961
280,443

Gastritis-duodenitis (Watanabe et al.91)
IBS Phecode 564.1 (Lee Lab)
Diverticular disease (Watanabe et al.91)
IBD (Liu et al.49)

14,477
5548
14,028
12,882

286,314
334,783
286,763
21,770

300,791
340,331
300,791
34,652

European

UKB data code described in Wu et al.22,a
Full European data subset from the Lee Lab
UKB treatment/medication code:
lansoprazole91
Main ICD10: K29 Gastritis and duodenitis91
Full European data subset from the Lee Lab
Main ICD10: K57 Diverticular disease91
Data from the IBD genetic consortium49

The ‘clinically diagnosed AD’ combined data from three case–control cohorts (N = 79,145). ‘AD-by proxy’ data were based on the UKB phenotype deﬁnition of individuals whose biological parents were
affected by AD. The parent’s current age, and where relevant, age at death were reported along with this GWAS data. The genetic correlation between the ‘clinically diagnosed AD’ and the ‘AD-by proxy’
is high at 0.8121, providing strong evidence or justiﬁcation for combining them as more comprehensively described in the associated publication21.
AD Alzheimer’s disease, GERD and GORD gastroesophageal reﬂux disease, PUD peptic ulcer disease, PGM GWAS combining disease-diagnosis of PUD and/or GERD and/or medications for their
treatments, IBS irritable bowel disease, IBD inﬂammatory bowel disease, ICD International Classiﬁcation of Diseases, UKB United Kingdom Biobank.
aUKB data code for case deﬁnition was from death register, primary care, hospital admissions data, self-report only, and other sources as described in the original publication Wu et al.22. The replication
set data were used for reproducibility testing in LDSC and SECA analyses, and partly in LCV analysis.

Brieﬂy, SECA performs a bi-directional analysis, assessing concordance in the direction of the effect of AD-associated SNPs
(data set 1) on each of the GIT disorders (data set 2) and vice
versa. First, we conducted two rounds of P-value informed LD
clumping (ﬁrst clumping: -clump-r2 0.1, -clump-kb 1000; second
clumping: -clump-r2 0.1, -clump-kb 10000) using PLINK 1.9030.

SECA subsequently assesses (using Fisher’s test) the presence of
excess SNPs in which the direction of effects is concordant across
144 subsets of data set 1 (AD GWAS) and data set 2 (each of the
GIT traits GWAS).
We found a positive and signiﬁcant concordance of SNP risk
effect across the AD (data set 1) and each of the GIT GWAS (data
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Table 2 Genetic correlation between AD and GIT disorders.
Trait 1

Trait 2
al.21)

AD (Jansen et
Excluding APOE and MHC regions

AD (Jansen et al.21) with APOE region

al.)23

GERD-UKBB_QSKIN (An et
PUD (Wu et al.22)
PGM (Wu et al.22)
Gastritis-duodenitis Phecode 535
IBS (Wu et al.22)
Diverticulosis Phecode 562
IBD (Wu et al.22)
GERD-UKBB_QSKIN An et al 201923
PUD (Wu et al.22)
PGM (Wu et al.22)
Gastritis-duodenitis Phecode 535
IBS (Wu et al.22)
Diverticulosis Phecode 562
IBD (Wu et al.22)

rg

se

P

0.25
0.28
0.22
0.24
0.19
0.15
0.07
0.23
0.26
0.21
0.22
0.18
0.14
0.06

0.03
0.05
0.03
0.04
0.05
0.04
0.05
0.04
0.05
0.04
0.05
0.05
0.03
0.04

8.19 × 10−18
3.70 × 10−7
2.38 × 10–14
2.40 × 10−8
1.10 × 10−4
2.97 × 10–5
9.94 × 10−2
1.20 × 10−10
4.25 × 10−7
3.56 × 10−9
1.21 × 10−5
7.61 × 10−5
6.58 × 10−5
1.72 × 10−1

We applied Bonferroni adjustment for testing the effects of seven GIT traits on AD (0.05/7 = 7.1 × 10−3), and all genetic correlation results surviving this cut-off were considered signiﬁcant while those
having P < 0.05 were regarded nominally signiﬁcant.
AD Alzheimer’s disease, GIT gastrointestinal tract, GERD gastroesophageal reﬂux disease, PUD peptic ulcer disease, IBS irritable bowel syndrome, PGM GWAS combining disease-diagnosis of PUD and/
or GERD and/or medications for their treatments, IBD inﬂammatory bowel disease, rg genetic correlation, se standard error, P P value, MHC major histocompatibility complex.

Table 3 SECA results: primary test for concordant SNP effects.
Primary test for concordant SNP effects between AD and GIT traits
Trait 1

Trait 2

Direction

SNP sets ratio

Ppermuted

AD (Jansen et al.21)
Excluding APOE and MHC regions

GERD-UKBB_QSKIN An et al.23
PUD (Wu et al.22)
PGM (Wu et al.22)
Gastritis-duodenitis Phecode 535
IBS (Wu et al.22)
Diverticulosis Phecode 562
IBD (Wu et al.22)

+
+
+
+
+
+
+

144/144
139/144
144/144
144/144
133/144
130/144
42/144

0.001a
0.001a
0.001a
0.001a
0.001a
0.001a
0.018a

Primary test for concordant SNP effects between GIT traits and AD
Trait 1

Trait 2

Direction

SNP sets ratio

Ppermuted

GERD-UKBB_QSKIN An et al.23
PUD (Wu et al.22)
PGM (Wu et al.22)
Gastritis-duodenitis Phecode 535
IBS (Wu et al.22)
Diverticulosis Phecode 562
IBD (Wu et al.22)

AD (Jansen et al.21)
Excluding APOE and MHC regions

+
+
+
+
+
+
+

144/144
138/144
141/144
135/144
118/144
73/144
19/144

0.001a
0.001a
0.001a
0.001a
0.001a
0.006a
0.084

AD Alzheimer’s disease, GIT gastro-intestinal tract, GERD gastroesophageal reﬂux disease, PUD peptic ulcer disease, IBS irritable bowel syndrome, PGM GWAS combining disease-diagnosis of PUD and/
or GERD and/or medications for their treatments, IBD inﬂammatory bowel disease, SNP single-nucleotide polymorphism, P P value, MHC major histocompatibility complex.
aThe number of SNP subsets with nominally signiﬁcant concordant effects is signiﬁcantly MORE than expected by chance, indicating signiﬁcant concordance of genetic risk between the pairs of traits.

set 2) including IBD (Table 3). For example, of the total 144 SNP
subsets tested with AD as data set 1 (Table 3), all 144 (for GERD,
PGM and gastritis-duodenitis), 139 (PUD), 133 (IBS), 130
(diverticulosis) and 42 (IBD) produced Fisher’s exact tests with
at least nominally signiﬁcant effect concordance (odds ratio
[OR] > 1 and P < 0.05). The empirical P values (Ppermuted) for the
signiﬁcant associations, adjusting for the 144 SNP subsets tested
(using permutations of 1000 replicates), range from 0.001 to 0.018
(Table 3). These results are signiﬁcantly more than expected by
chance, supporting evidence of genetic overlap between AD and
the GIT traits.
By changing the direction of the analysis (in a bidirectional
assessment), we tested each of the GIT traits as data set 1 against
AD as data set 2 (Table 3). The results indicate evidence of a
strong genetic overlap between AD and GERD, PUD, PGM,
gastritis-duodenitis, IBS and diverticulosis. The results also
suggest (except for IBD) that SNPs that are strongly associated
4

with AD inﬂuence the named GIT traits and vice versa. Overall,
ﬁndings in SECA are largely consistent with those of LDSC,
except in the case of IBD—highlighting how SECA differs from
(capacity for a bidirectional assessment) as well as complements
LDSC. Notably, and like LDSC, SECA found a signiﬁcant
association between AD and GIT traits with or without the
APOE region (Table 3 and Supplementary Data 4). Further,
replication analyses in SECA produced largely consistent ﬁndings
as with LDSC (Supplementary Data 5 and 6).
SNPs and loci shared by AD and GIT disorders. Leveraging the
signiﬁcant genetic overlap and correlation as well as the substantial
GWAS sample sizes, we performed cross-disorder meta-analyses of
AD with GERD and PUD. The GWAS for PGM has many cases
and overall large sample size (Table 1) and is strongly correlated
with GERD (rg = 0.99, P = 0.000) and PUD (rg = 0.76,
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P = 4.41 × 10−101) [Supplementary Data 7], hence, we also utilised
it in a meta-analysis with AD. We aimed at identifying SNPs and
loci which were not genome-wide signiﬁcant in the individual AD
or GIT disorder GWAS (i.e., 5 × 10−8 < PGWAS-data < 0.05) but
reached the status (Pmeta-analysis < 5 × 10−8) following a metaanalysis. We additionally identiﬁed SNPs and loci which were
already established (PGWAS-data < 5 × 10−8) in AD (Sentinel AD
SNPs/loci), but which, following GWAS meta-analyses, were
similarly associated with a GIT disorder, and vice versa. Brieﬂy, our
GWAS meta-analyses identiﬁed shared SNPs and susceptibility
loci, some of which are putatively novel for AD or GIT disorders.
First, a meta-analysis of AD and GERD identiﬁed a total
of 119 SNPs reaching genome-wide signiﬁcant association
(Pmeta-analysis < 5 × 10−8, Supplementary Data 8), from which we
characterised seven independent (r2 < 0.1) genomic loci—1p31.3,
1q31.1, 3p21.31, 6p21.32, 17q21.32, 17q21.33, 19q13.32 (Table 4).
Many SNPs reaching genome-wide signiﬁcance in these loci
were not genome-wide signiﬁcant in the individual AD and
GIT GWAS we analysed but reached the status in the cross-trait
meta-analyses (Table 3). Given this premise (that is,
PGWAS-data > 5 × 10−8 < Pmeta-analysis), the observation that some
of the identiﬁed loci are known for AD or GIT traits (from other
studies) provides support for our cross-trait analysis ﬁndings.
Speciﬁcally, two of the identiﬁed loci: (1p31.3 [near PDE4B], and
3p21.31 [near SEMA3F]) were not previously genome-wide
signiﬁcant for AD (to our knowledge), indicating they are
putatively novel for the disorder. Similarly, three of the seven loci:
(17q21.32 [ZNF652], 17q21.33 [PHB], and 19q13.32 [TOMM40,
APOC2, KLC3, ERCC2]) are putatively novel for GERD given we
have no evidence they were previously genome-wide signiﬁcant
for the disorder. A locus at 1q31.1 (near BRINP3) was putatively
novel for both AD and GERD at the time of our analysis but has
now been reported in a recent GERD multi-trait analysis31—
providing support for our ﬁnding. The remaining locus, 6p21.32
(near genes HLA-DQA2 and HLA-DRA) is known for both AD32
and GIT disorders—IBD33, ulcerative colitis34 and Crohn’s
disease33—and now (in our study), GERD.
An additional 175 independent SNPs at 121 loci reached a
genome-wide suggestive association (Pmeta-analysis < 1 × 10−5,
Supplementary Data 9), replicating some of the genome-wide
signiﬁcant loci, including: 1p31.3 (PDE4B, lead SNP: rs2840677)
and 1q31.1 (BRINP3, rs10753964) for AD and GERD. Also, some
of the well-established (sentinel) loci for AD in our GWAS
showed evidence of association with GERD (Supplementary
Data 10) at 8p21.2 (near gene PTK2B, and CHRNA2,
rs28834970). Other AD sentinel loci shared with GERD include:
19q13.32 (near NECTIN2, lead SNP: rs12980613), and 19q13.32
(near KLC3, rs77988534) [Supplementary Data 10]. Known
(sentinel) GERD loci were similarly associated with AD as
summarised in Supplementary Data 10.
Second, following a meta-analysis of AD and PUD GWAS, a
total of 22 SNPs, at six genomic loci, reached a genome-wide
signiﬁcance (Pmeta-analysis < 5 × 10−8, Supplementary Data 11).
The identiﬁed loci here include 2q37.1, 6p21.32, 8p21.1, 17p13.2,
19q13.32 and 19q13.41 (Table 4). Of the loci found in the AD and
GERD meta-analysis, four were replicated in the AD and PUD
meta-analysis. Two of these four loci, the 19q13.32 (near BCL3,
rs28363848), and the 6p21.32 (HLA-DRA, rs9270599), were
replicated at a genome-wide level of signiﬁcance. The remaining
two loci—HYAL2, 3p21.31, P(FE) = 5.24 × 10−3, rs709210; and
PDE4B, 1p31.3, P(FE) = 2.94 × 10−4, rs6695557 (Supplementary
Data 12)—were replicated at 7.14 × 10−3 level. In addition to the
6p21.32 (HLA-DRA, rs9270599), two of the identiﬁed loci: at
8p21.1 (near SCARA3), and 2q37.1 (near ATG16L1) have been
reported for AD (SCARA335, ATG16L121,32,36), and GIT traits
(SCARA3: gastric or stomach ulcer37, ATG16L1: IBD38, ulcerative
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colitis and Crohn’s disease33,39). Supplementary Data 13 presents
24 independent SNPs, at 21 genomic loci, reaching genome-wide
suggestive association (Pmeta-analysis < 1 × 10−5) for AD and PUD.
Third, given its large sample size and strong genetic correlation
with GERD and PUD, we performed a meta-analysis of PGM
with AD thereby identifying 42 SNPs (Supplementary Data 14) at
seven independent loci (Table 4) reaching a genome-wide
signiﬁcance level. This analysis replicated, at a genome-wide
level (Pmeta-analysis < 5 × 10−8), ﬁve of the seven genome-wide loci
found in the AD and GERD meta-analysis including 1p31.3,
3p21.31, 6p21.32, 17q21.33 and 19q13.32. Additional loci found
in the AD and PGM meta-analysis such as 16q22.1 and 1q32.2
were at least genome-wide suggestive (Pmeta-analysis < 1 × 10−5) in
the AD and GERD analysis, supporting their involvement in the
disorders. An additional 23 SNPs, at three loci, were genomewide suggestive (Pmeta-analysis < 1 × 10−5) in the AD and PGM
meta-analysis (Supplementary Data 15). Of these, the rs33998678
SNP (16q22.1, IL34) is in strong LD (r2 = 0.91) with a genomewide signiﬁcant locus found in the AD vs PGM analysis
(rs34644948, at 16q22.1, MTSS2, Table 4), providing more
support for its involvement in AD and GIT traits (GERD and
PUD). Similarly, the rs663576 SNP (at 17q21.32, PHOSPHO1) is
moderately correlated (r2 = 0.41) with a genome-wide signiﬁcant
SNP (rs2584662 at 17q21.33, PHB, Table 4), identiﬁed in the
meta-analysis. This locus (17q21.33) was found in AD and GERD
meta-analysis (SNP rs2584662 near PHB), supporting its
involvement in AD and the GIT traits. Supplementary Data 10
summarises the sentinel AD loci associated with PGM and
vice versa.
Association of identiﬁed loci with other traits. Seven loci
reached a genome-wide signiﬁcance in the meta-analysis of AD
and GERD GWAS; most of these loci were replicated in the AD
vs PUD and/or AD vs PGM meta-analysis. We queried each of
the associated loci for pleiotropic associations with other traits
using the GWAS catalogue (https://www.ebi.ac.uk/gwas) and the
Open Targets Genetics (https://genetics.opentargets.org) platforms. For three of the loci—1p31.3 (near PDE4B), 3p21.31 (near
SEMA3F), and 1q31.1 (near BRINP3)—we have no evidence of
their previous association with AD, at a genome-wide level
(P < 5 × 10−8). However, and potentially supportive of our ﬁndings, the loci have been reported for AD-related phenotypes such
as cognitive traits.
For example, PDE4B has pleiotropic associations with
intelligence40, educational attainment41, and sleep-related traits
such as insomnia42. The locus is also known for other disorders
including major depression, stress disorders, schizophrenia, and
multiple sclerosis43—putative comorbidities of AD44,45—among
other traits. The loci harbouring SEMA3F and BRINP3 have
similarly been reported for intelligence (SEMA3F46), general
cognitive ability (SEMA3F40), educational attainment
(SEMA3F47, BRINP341), insomnia (SEMA3F and BRINP342)
and BMI (SEMA3F and BRINP3). Sex hormone-binding globulin
levels48 and multi-site chronic pain are some of the traits that
have also been linked with SEMA3F. Interestingly, BMI, cognitive
traits such as intelligence, cognitive performance and even sleeprelated traits have been associated with GERD31. Taken together,
and in further support of their relationship, this observation,
suggests that GERD may share genetic links with certain ADrelated phenotypes including cognitive and sleep-related traits.
Further, our analysis consistently identiﬁed and replicated the
19q13.32 locus (mapped genes: TOMM40, APOC2, KLC3,
ERCC2, BCL3, and CD33) as shared by AD and GIT disorders.
While this locus is well known for AD, it has also been linked
with GIT traits including IBD49 (SYMPK, lead SNP: rs16980051,
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Locus

Lead SNPs

Chr

BP

EA

85.75
91.93
96.02
92.74
0.00
0.00
0.00
0.00
94.99
0.00
50.22
0.00
26.29
76.92
31.11
41.06
58.20
5.22
66.10
57.16
84.60
13.54
93.99
93.64
61.35
0.00
0.00
0.00
0.00

G
A
G
G
G
G
G
T
G
C
G
C
G
A
T
C
A
C

I2

C
A
T
C
T
T
A
C
C
G
C

NEA

Meta-analysis model use was the RE2. RE2: GWAS meta-analysis method that adjusts for SNP effects heterogeneity.
SNP single-nucleotide polymorphism, Chr chromosome, EA effect allele, NEA non-effect allele, I2 I-square for heterogeneity assessment, Se standard error, P P value.

SNPs and loci reaching genome-wide signiﬁcance after a meta-analysis of AD GWAS and GERD GWAS
rs12058296
1
rs12058296
1
66402424
A
rs2503185
1
66461401
G
rs12561863
2
rs12561863
1
190897608
A
rs3774745
3
rs3774745
3
50204745
T
rs28895026
4
rs28895026
6
32391695
C
rs8067459
5
rs2584662
17
47444113
C
rs2584662
17
47470487
C
rs11083749
6
rs1132899
19
45384105
T
rs1132899
19
45448036
T
rs117501883
7
rs117501883
19
45841296
A
rs76692930
19
45875851
T
SNPs and loci reaching genome-wide signiﬁcance after a meta-analysis of AD GWAS and PUD GWAS
rs36133610
1
rs36133610
2
234067884
A
rs9270599
2
rs9270599
6
32561656
G
rs530324
3
rs530324
8
27491186
C
rs73976310
4
rs73976310
17
5014212
A
rs28363848
5
rs28363848
19
45257201
T
rs3852865
6
rs3852865
19
51714065
A
rs7245846
19
51731176
A
SNPs and loci reaching genome-wide signiﬁcance after a meta-analysis of AD GWAS and PGM GWAS
rs2840677
1
rs12058296
1
66333877
A
rs6695557
1
66349013
A
rs12058296
1
66402424
A
rs4147104
2
rs4147104
1
207882194
A
rs709210
3
rs7642934
3
50357869
A
rs7642934
3
50174848
A
rs2858331
4
rs2858331
6
32681277
G
rs28895026
6
32391695
C
rs34644948
5
rs34644948
16
70681658
T
rs2584662
6
rs2584662
17
47470487
C
rs11083749
7
rs11083749
19
45384105
T

Independent SNPs

Table 4 Genome-wide signiﬁcant independent SNPs and loci for AD and GIT disorders.

PDE4B/1p31.3
PDE4B/1p31.3
PDE4B/1p31.3
CD46/1q32.2
HYAL2/3p21.31
SEMA3F/3p21.31
HLA-DQA2/6p21.32
HLA-DRA/6p21.32
MTSS2/16q22.1
PHB/17q21.33
TOMM40/19q13.32

ATG16L1/2q37.1
HLA-DRA/6p21.32
SCARA3/8p21.1
USP6/17p13.2
BCL3/19q13.32
CD33/19q13.41
CD33/19q13.41

PDE4B/1p31.3
PDE4B/1p31.3
BRINP3/1q31.1
SEMA3F/3p21.31
HLA-DRA/6p21.32
ZNF652/17q21.32
PHB/17q21.33
TOMM40/19q13.32
APOC2/19q13.32
KLC3/19q13.32
ERCC2/19q13.32

Nearest coding
genes/cytoband
3.22 × 10−5
9.53 × 10−4
5.76 × 10−3
2.55 × 10−4
1.48 × 10−7
2.15 × 10−7
1.54 × 10−7
2.46 × 10−7
5.41 × 10−8
7.13 × 10−8
3.18 × 10−6
5.85 × 10−8
5.60 × 10−8
3.32 × 10−7
7.04 × 10−8
5.63 × 10−8
1.63 × 10−7
1.19 × 10−7
5.73 × 10−3
3.02 × 10−3
3.22 × 10−5
1.02 × 10−6
1.55 × 10−2
7.47 × 10−3
1.24 × 10−7
1.48 × 10−7
1.98 × 10−7
1.98 × 10−7
1.98 × 10−7

1.24 × 10−8
9.12 × 10−9
2.27 × 10−8
1.20 × 10−8
1.04 × 10−8
1.81 × 10−8
2.32 × 10−8
2.43 × 10−8
8.46 × 10−9
5.02 × 10−9
5.47 × 10−9
4.39 × 10−8
2.78 × 10−8
3.08 × 10−10
5.43 × 10−9
2.11 × 10−8
3.94 × 10−9
2.84 × 10−8

AD
P value

1.05 × 10−8
3.44 × 10−8
1.68 × 10−8
2.01 × 10−9
2.06 × 10−8
3.07 × 10−8
7.72 × 10−9
2.63 × 10−8
1.19 × 10−8
8.96 × 10−9
3.51 × 10−8

Metaanalysis
P value

2.20 × 10−7
1.89 × 10−7
8.68 × 10−6
6.12 × 10−4
6.28 × 10−8
8.19 × 10−8
1.18 × 10−4
8.38 × 10−3
3.13 × 10−2
4.91 × 10−3
3.45 × 10−2

4.90 × 10−2
2.72 × 10−2
2.00 × 10−3
2.70 × 10−2
2.60 × 10−2
9.90 × 10−3
4.00 × 10−2

1.74 × 10−5
9.60 × 10−7
1.05 × 10−7
1.64 × 10−7
4.26 × 10−2
4.48 × 10−2
1.02 × 10−2
3.14 × 10−2
5.53 × 10−3
3.78 × 10−2
8.32 × 10−4

GIT disorders
P value
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P

0.879
0.502
0.612
0.770
0.631
0.133
0.196
0.438
0.483
0.773
0.885
0.497
0.00034
0.0025
−0.002
−0.00291
−0.001
0.007
0.0046
0.0032
0.0034
−0.00076
−0.00097
0.00073

Intercept
P

—
—
—
0.053
—
0.661
—
0.892
—
—
—
—
—
—
—
0.0331
—
0.009
—
0.010
—
—
—
—

Corrected beta
P

0.276
0.361
0.60
0.277
0.123
0.337
0.277
0.626
0.601
0.884
0.115
0.895
−0.052
0.0136
0.036
0.021
−0.061
0.023
−0.085
0.043
−0.055
−0.001
0.254
−0.0005

Raw beta
Global test P

0.113
0.435
0.113
0.0104
0.231
0.017
0.034
0.0012
0.094
0.316
0.327
0.316
0.362
0.597
0.504
0.658
0.391
0.199
0.098
0.888
0.397
0.811
0.231
0.607

P
Beta
P
P

0.266
0.351
0.651
0.238
0.112
0.322
0.267
0.623
0.597
0.883
0.104
0.895

Beta

GERD
AD
PUD
AD
PGM
AD
Gastritis-Da
IBSa
Diverticular
AD
IBD
AD
AD (28)
GERD (24)
AD (28)
PUD (8)
AD (28)
PGM (17)
AD (28)
AD (28)
AD (28)
Diverticular (16)
AD (28)
IBD (24)

−0.053
0.014
0.036
0.021
−0.061
0.023
−0.085
0.043
−0.055
−0.001
0.254
−0.0005

Beta

−0.059
−0.053
0.071
0.055
−0.045
−0.148
−0.173
−0.016
−0.12
0.007
0.277
0.004

MR-PRESSO
MR-Egger
Weighted median
IVW
Outcome
Exposure (nSNPs)

Table 5 Summary of MR analysis results for AD and GIT disorders.

Results of causal association analysis between AD and GIT
disorders. We assessed the potential causal relationship between
AD (as the outcome variable) and GERD (as the exposure variable) using the two-sample MR method. We found no evidence of
a causal relationship between AD and GERD, irrespective of the
direction of the analysis (AD or GERD as the outcome or
exposure variable) [Table 5]. For sensitivity testing, we implemented three additional models of MR analysis—MR-Egger,
weighted median, and the MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier). Results from these
methods agree with those of the Inverse Variance Weighted
(IVW) model supporting a lack of evidence for a causal association between AD and GERD (Table 5 and Supplementary
Data 19). We carried out further MR analysis assessing AD
against each of PUD, PGM, IBS, diverticular disease, and IBD,
and vice versa. Findings similarly reveal no evidence for a causal
relationship between AD and each of the GIT disorders assessed
(Supplementary Data 19).
We also used the Latent Causal Variable (LCV) approach29 to
test for a causal relationship between AD and each of the GIT
disorders. The results of LCV suggest a partial causal inﬂuence of
gastritis-duodenitis (genetic causal proportion [GCP] = −0.69,
P = 0.0026), on AD (Table 6). The result was in the reverse
direction for diverticular disease (GCP = 0.23, P = 0.000272),
suggesting AD may partially cause diverticular disease. Using
another set of GWAS (Table 6), we tested the reproducibility of
the partial causal association results for gastritis-duodenitis and
diverticular disease, neither of which was reproduced, hence, the
need for the ﬁndings to be further assessed in future studies.

0.860
0.920
0.211
0.122
0.769
0.837
0.273
0.123
0.105
0.905
0.094
0.526

Shared genomic regions identiﬁed in GWAS-PW analysis.
Using a colocalization analysis in GWAS-PW27, we assessed
shared genomic regions between AD and each of GERD and
PGM (Supplementary Data 18). The results of this analysis
conﬁrm all the loci identiﬁed in the meta-analyses (except on
chromosome 3) are shared by AD and the respective GIT traits
(model 4 posterior probability [PPA 4] > 0.9, Supplementary
Data 18). While the ﬁndings also suggest that the causal variants
might be different (PPA 3 < 0.5), we note that when variants in a
locus are in strong LD, which may be the case in this study,
GWAS-PW is limited in its ability to correctly distinguish model
3 (PPA 3) from model 4 (PPA 4)27. Additional shared genomic
regions, in chromosomes 1, 6, 16, 17 and 19 having PPA 4 > 0.90
were identiﬁed for AD and the GIT traits (Supplementary
Data 18). Also, we identiﬁed a locus on chromosome 17, having
PPA 3 > 0.80, and implicating the SNP rs2526380 (17q22, near
TSPOAP1) in both AD and GERD. The posterior probability that
this SNP is a causal variant for both AD and GERD under model
327 is high at 0.99 (Supplementary Data 18).

0.011
−0.002
0.144
0.025
−0.016
−0.005
−0.101
0.142
−0.214
−0.001
0.365
−0.003

MR-Egger Intercept

GRCh37: 19:46,345,886), and gut microbiota50, thus, highlighting
an association of AD with not only GIT disorders, but also the gut
microbiome. This premise is important given previous evidence
of genetic links between dysbiosis, neurological (AD, for instance)
and GIT disorders15,22,51,52, and may underscore the need for a
renewed focus on the genetics of gut-brain connection (including
the gut microbiome) to better understand the underlying
mechanisms of AD. Similar to other identiﬁed loci, the
19q13.32 locus also displays pleiotropic association with many
AD-related phenotypes: intelligence53, cognitive impairment test
score54, t-tau and beta-amyloid 1–42 measurements, hippocampal atrophy rate, memory performance, and educational
attainment41. Supplementary Data 16 and 17 summarise other
traits previously reported for loci at 6p21.32 (near HLA-DRA)
and 17q21.32 (near ZNF652 and PHB).
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nSNP number of SNPs utilised as instrumental variables, SNP single-nucleotide polymorphism, AD Alzheimer’s disease, GERD gastroesophageal reﬂux disease, PUD peptic ulcer disease, PGM GWAS combining disease-diagnosis of PUD and/or GERD and/or medications for
their treatments, Diverticular diverticular disease, IBS irritable bowel syndrome, IBD inﬂammatory bowel disease, IVW inverse variance weighted, P P value, MR-PRESSO Mendelian Randomization Pleiotropy RESidual Sum and Outlier, Gastritis-D gastritis-duodenitis.
aOnly one genome-wide signiﬁcant SNPs available for IBS, and 3 for Gastritis-D, so we are unable to carry out MR using the traits as the exposure variable. Note spaces marked with a dash indicate that there were no outlier SNPs and hence there was no outlier corrected results
in the MR-PRESSO analysis.
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Conversely, we found a signiﬁcant association between AD and
lansoprazole use (GCP = −0.38, P = 0.001129).
Gene-based association analysis. Using SNPs that overlapped
AD and GERD GWAS, we performed gene-based analyses in
MAGMA (implemented in the FUMA55 platform), thereby
identifying a total of 18,929 protein-coding genes for each of the
traits. Applying a threshold P-value of 2.64 × 10−6 (0.05/18929—
Bonferroni correction for testing 18,929 genes), we identiﬁed 64
genome-wide signiﬁcant (Pgene < 2.64 × 10−6) genes for AD
(Supplementary Data 20), 44 for GERD (Supplementary Data 21)
and 75 for PGM (Supplementary Data 22). Using the Fisher’s
Combined P-value (FCP) method, a total of 46 genome-wide
signiﬁcant (PFCP < 2.64 × 10−6) genes shared by AD and GERD
were identiﬁed (Supplementary Data 23), 10 of which were not
previously signiﬁcant in our AD or GERD GWAS, at the
Pgene < 2.64 × 10−6 threshold, adjusting for multiple testing
(Table 7), but are in known AD or GIT trait loci. It is noteworthy
Table 6 Partial causality assessment using the Latent Causal
Variable approach.
Trait 1

Trait 2

GCP

SE

P

AD

GERD
PUD
PGM
Gastritis-duodenitis
(Main ICD10: K29)
IBS
Diverticular disease
(Main ICD10: K57)
Lansoprazole

−0.01
0.49
−0.45
−0.69

0.58
0.32
0.37
0.27

0.64
0.24
0.22
0.0026

0.35
0.23

0.29
0.10

0.38
0.000272

−0.38

0.17

0.001129

AD Alzheimer’s disease, GCP genetic causal proportion, SE standard error, P P value, GERD
gastroesophageal reﬂux disease, PUD peptic ulcer disease, PGM GWAS combining diseasediagnosis of PUD and/or GERD and/or medications for their treatments.

that some of the identiﬁed AD and GERD shared genes are in
chromosomal locations found in our meta-analysis, including
1p31.3 (PDE4B), 3p21.31, (SEMA3F, HYAL2, IP6K1), 6p21.32
(HLA-DRA) and 19q13.32 (Supplementary Data 23). Combining
P-values by weighting based on sample size (the weighted
Stouffer's method) produced a similar pattern of results (as the
FCP) for AD and GERD (Supplementary Data 24). We also
replicated a similar pattern of ﬁndings in gene-based analysis
(and FCP) using the AD and the PGM GWAS (Table 7 Supplementary Data 25).
Biological pathways and mechanisms shared by AD and GIT
disorders. We performed pathway-based functional enrichment
analyses in the g: Proﬁler platform56 to functionally interpret
genes overlapping AD and GIT disorders and gain biological
insight from their commonalities. First, we investigated genes
overlapping AD and GERD (at Pgene < 0.05, FCP < 0.02) and
identiﬁed several biological pathways that were overrepresented
(Fig. 2 and Supplementary Data 26), implying they have a role in
the mechanisms underlying both AD and GERD. Pathways
related to membrane trafﬁcking and metabolism, alteration,
lowering or inhibition of lipids were signiﬁcantly enriched
(Supplementary Data 26). These included plasma lipoprotein
assembly, remodelling, and clearance (Padjusted = 2.01 × 10−3),
cholesterol metabolism (Padjusted = 4.99 × 10−2), plasma lipoprotein assembly (Padjusted = 3.45 × 10−5), and triglyceride-rich
plasma lipoprotein particle (Padjusted = 5.23 × 10−9), among others. Also, lipase inhibitors (Padjusted = 6.08 × 10−3) and the statin
(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors)
pathway (Padjusted = 3.99 × 10−2) were signiﬁcantly enriched for
AD and GERD (Supplementary Data 27), suggesting mechanisms
of these medications may ﬁnd therapeutic application in AD and
GIT disorders.
Pathways related to the immune system were also overrepresented for both AD and GERD as evidenced by the
identiﬁcation of immune or autoimmune-related disorders such

Table 7 Shared genes reaching genome-wide signiﬁcance for AD and GIT traits.
SYMBOL

CHR

CYTOBAND

START

Genome-wide signiﬁcant genes shared by AD and GERD
MON1A
3
3p21.31
49946302
IP6K1
3
3p21.31
49761727
HLA-DRA
6
6p21.32
32407619
PGBD1
6
6p22.1
28249314
NKAPL
6
6p22.1
28227098
ZKSCAN8
6
6p21
28109688
C6orf10
6
6p21.32
32256303
TMEM106B
7
7p21.3
12250867
ZNF689
16
16p11.2
30613879
FOXA3
19
19q13.32
46367247
Genome-wide signiﬁcant genes shared by AD and PGM
CR1L
1
1q32.2
207818458
HYAL2
3
3p21.31
50355221
C6orf10
6
6p21.32
32256303
NKAPL
6
6p22.1
28227098
CLIC1
6
6p21.33
31698358
ZSCAN9
6
6p22.1
28192664
TRIM39-RPP21
6
6p22.1
30297359
ZSCAN12
6
6p22.1
28346732
BAG6
6
6p21.33
31606805
FBXO46
19
19q13.32
46213887
RSPH6A
19
19q13.32
46298968

STOP

P-AD

P-GIT

FCP-value

49967606
49823975
32412823
28270326
28228736
28127250
32339684
12282993
30635333
46377055

2.42E−02
1.47E−02
1.38E−05
9.62E−03
1.33E−03
2.11E−02
2.96E−05
1.33E−04
9.71E−06
6.31E−04

3.14E−06
1.05E−05
7.06E−06
4.08E−06
4.64E−05
3.92E−06
4.20E−03
1.04E−03
1.55E−02
5.45E−05

1.33E−06
2.57E−06
2.34E−09
7.08E−07
1.09E−06
1.43E−06
2.10E−06
2.32E−06
2.51E−06
6.25E−07

207911761
50360337
32339684
28228736
31707540
28201260
30314631
28367511
31620482
46234162
46318577

2.70E−05
3.63E−02
2.32E−05
1.33E−03
7.64E−04
1.92E−03
9.07E−03
1.10E−02
6.68E−03
7.62E−04
2.76E−04

4.47E−03
3.49E−06
3.64E−04
7.31E−06
1.88E−05
1.46E−05
3.63E−06
7.36E−06
1.61E−05
4.19E−05
1.16E−04

2.05E−06
2.14E−06
1.65E−07
1.89E−07
2.74E−07
5.17E−07
6.01E−07
1.40E−06
1.84E−06
5.83E−07
5.85E−07

Note: genes reported in this Table were not previously genome-wide in the gene-based analysis for the individual AD and GIT GWAS analysed but reached the status following FCP analysis.
CHR chromosome, P-AD P value for Alzheimer’s disease, P-GIT P value for gastrointestinal tract trait, FCP Fisher’s combined P value, GERD gastroesophageal reﬂux disease, PGM GWAS combining diseasediagnosis of PUD and/or GERD and/or medications for their treatments.
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Fig. 2 Clusters of signiﬁcantly enriched biological pathways for AD and GERD. a KEGG: Kyoto Encyclopedia of Genes and Genomes pathways: intestinal
immune network (allograft rejection, intestinal immune network for IGA production, type 1 diabetes mellitus, systemic lupus erythematous, antigen
processing and presentation, graft-versus-host disease, asthma), and cholesterol metabolism (cholesterol metabolism). b Gene Ontology: Cellular
Components: side membrane vesicle (lumenal side of membrane, MHC class II protein complex, integral component of lumenal side of endoplasmic
reticulum [ER] membrane, clathrin-coated endocytic vesicle membrane, late endosome, ER to Golgi transport vesicle membrane, coated vesicle membrane,
lumenal side of ER membrane, MHC protein complex, COPII-coated ER to Golgi transport vesicle, transport vesicle membrane, late endosome membrane),
and plasma lipoprotein particle (chylomicron, very low-density lipoprotein [VLDL] particle, triglyceride-rich plasma lipoprotein particle, plasma lipoprotein
particle, lipoprotein particle, LDL lipoprotein particle). c Gene Ontology: Molecular Function: peptide antigen binding (peptide binding, peptide antigen
binding, MHC class II receptor activity) and lipase inhibitor activity (lipase inhibitor activity). d Gene Ontology: Biological Pathway: lipoprotein particle
clearance (phospholipid efﬂux, VLDL particle clearance, regulation of plasma lipoprotein particle levels, plasma lipoprotein particle clearance, chylomicron
remnant clearance, regulation of lipid catabolic process, regulation of VLDL particle clearance, protein-lipid complex assembly, plasma lipoprotein particle
organisation, regulation of phospholipid catabolic process, VLDL particle assembly, regulation of lipid localisation, glycolipid catabolic process, triglyceriderich lipoprotein particle clearance, high density lipoprotein particle remodelling), receptor signalling pathway (T cell receptor signalling pathway, interferongamma-mediated signalling pathway, antigen receptor-mediated signalling pathway), membrane adhesion cell (cell-cell adhesion via plasma membrane
adhesion molecules, homophilic cell adhesion via plasma membrane adhesion molecules), and negative regulation type (negative regulation of type I
interferon production). e Reactome, Wiki pathway and Transcription Factor Binding site: assembly clearance plasma (statin pathway, NR1H2 and NR1H3mediated signalling, plasma lipoprotein assembly, remodelling, and clearance, plasma lipoprotein clearance, NR1H3 and NR1H2 regulated gene expression
linked to cholesterol transport and efﬂux, VLDL assembly, VLDL clearance, plasma lipoprotein assembly), interferon-gamma signalling (PD-1 signalling,
generation of second messenger molecules, interferon-gamma signalling phosphorylation of CD3 and TCR ZETA chains, translocation of ZAP-70 to
Immunological synapse), Factor: ZNF2 motif, and ZNF582 motif. Supplementary Data 26 provides additional details about these biological pathways. AD
Alzheimer’s disease, GERD gastroesophageal reﬂux disease.

as asthma (Padjusted = 3.53 × 10−3), systemic lupus erythematosus
(Padjusted = 7.88 × 10−3), and type I diabetes mellitus (Padjusted =
2.47 × 10−2). Other immune-related pathways identiﬁed include
the intestinal immune network for IgA production (Padjusted =
4.07 × 10−2), programmed cell death protein 1 (PD-1) signalling
(Padjusted = 5.24 × 10−3), translocation of ZAP-70 to immunological synapse (Padjusted = 2.44 × 10−3) and interferon-gamma
signalling pathways (Padjusted = 2.45 × 10−2) [Supplementary
Data 26].
Following enrichment mapping and auto-annotation, the
identiﬁed biological pathways were clustered into six themes of
biological mechanisms, namely: ‘lipoprotein particle clearance,’
‘receptor signalling pathway,’ ‘side membrane vesicle and cell
adhesion,’ ‘peptide antigen binding,’ ‘intestinal immune network,’
and ‘interferon-gamma signalling’ (Fig. 2). Moreover, a pathwaybased analysis using genes that overlapped AD and PGM GWAS

(at Pgene < 0.05) replicated some of the pathways identiﬁed for AD
and GERD, including ‘plasma lipoprotein assembly, remodelling,
and clearance’ (Padjusted = 3.01 × 10−4), ‘peptide antigen binding’
(Padjusted = 2.28 × 10−3), and ‘triglyceride-rich plasma lipoprotein
particle’ (Padjusted = 6.60 × 10−8) [Supplementary Data 27]. Also,
we performed pathway-based analysis separately for GERD and
AD GWAS, the full results of which are presented in
Supplementary Data 28 and 29, respectively.
Discussion
We present the ﬁrst comprehensive assessment (to the best of our
knowledge) of the shared genetics of AD with GIT disorders by
analysing large-scale GWAS summary data using multiple statistical genetic approaches. Consistent with previous conventional
observational studies3–9, our ﬁndings conﬁrm a risk-increasing
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relationship between AD and GIT disorders and provide insights
into their underlying biological mechanisms. In contrast to the
positive genetic correlation between AD and other GIT disorders,
LDSC found no signiﬁcant genetic correlation between AD and
IBD, which may be due to the relatively small number of cases
and sample size of the IBD GWAS. Based on the effective sample
size estimates, the IBD GWAS is underpowered compared to
other GIT data sets. Supporting this premise, SECA revealed a
signiﬁcant association between AD (as data set 1) against IBD (as
data set 2), but not the other way around. The AD GWAS has a
larger sample size, providing a more robust association on which
to condition (select independent) SNPs for concordance analysis
which may explain why the signiﬁcant association was not bidirectional unlike the case for other GIT traits. Future studies,
nonetheless, need to conﬁrm this relationship, as more powerful
IBD GWAS becomes available.
Evidence of signiﬁcant genetic overlap and correlation reﬂects
not only shared genetic aetiologies (biological pleiotropy) but also
suggests a possible causal association between AD and the GIT
traits (vertical pleiotropy). Using LCV, we detected a partial
causal association between AD and gastritis-duodenitis, lansoprazole, and diverticular disease. However, this partial causal
association was not evident in reproducibility testing. The
inconclusive LCV ﬁndings should be cautiously interpreted, and a
reassessment of the results, in future studies, is warranted. Conversely, all MR analyses provided no evidence for a signiﬁcant
causal relationship between AD and GIT traits, indicating that
shared genetics and common biological pathways may best
explain the association between AD and these GIT disorders.
We performed GWAS meta-analysis, thereby identifying seven
shared loci reaching genome-wide signiﬁcance for AD and GERD.
The loci, including 1p31.3 (PDE4B), 3p21.31 (SEMA3F, HYAL2),
6p21.32 (HLA-DRA), and 19q13.32 (TOMM40, APOC2, ERCC2,
BCL3, and KLC3), were replicated in AD vs PUD and AD vs PGM
meta-analyses and largely reinforced in colocalisation (GWASPW) as well as gene-based association analyses. Notably, the
independent SNP rs12058296 (1p31.3), mapped to the phosphodiesterase 4B (PDE4B) gene. Inhibition of PDE4B (or its subtypes)
has shown promise for inﬂammatory diseases57–60. Indeed, recent
evidence supports the potent anti-inﬂammatory, pro-cognitive,
neuro-regenerative, and memory-enhancing properties of PDE4
inhibitors (PDE4B, in particular61), making them plausible therapeutic targets for AD59,60 and GIT disorders58. Other identiﬁed
independent genome-wide signiﬁcant SNPs and loci mapped to
genes including CD46, SEMA3F, HLA-DRA, MTSS2, PHB, and
TOMM40. The CD46 gene is a complement regulator which is
bactericidal to Helicobacter (H) pylori62 and was also recently
identiﬁed for AD in a transcriptome analysis63, making it a plausible candidate in both AD and GIT disorders.
We identiﬁed biological pathways, signiﬁcantly enriched for
genes overlapping AD and GIT disorder (GERD, and PUD)
GWAS in pathway-based analyses. Notably, lipid-related, and
autoimmune pathways were overrepresented. There is a close link
between autoimmunity and lipid abnormalities64, and consistent
with previous studies65–69, our ﬁndings highlight the importance
of lipids homoeostasis in AD and GIT traits. In AD, for example,
hypercholesterolaemia is believed to increase the permeability of
the blood-brain barrier system, facilitating the entry of peripheral
cholesterol into the CNS, and resulting in abnormal cholesterol
metabolism in the brain65,66. Amyloidogenesis, alteration of the
amyloid precursor protein degradation, accumulation of Aβ, and
subsequent cognitive impairment have all been linked with elevated cholesterol in the brain66,70–72. Similarly, while the exact
roles of lipids in GIT disorders are unclear, H. pylori is believed to
cause or worsen abnormal serum lipid proﬁles through chronic
10

inﬂammatory processes, and eradication of the infection enhances lipid homoeostasis68,69.
The mechanisms of association between AD and lipid dysregulation relate to the ‘gut–brain axis’, alterations in GIT microbiota and the immune system10,66. Moreover, lipid dysregulation
is central to the interplay of AD, gut microbiota, and GIT
disorders10,66, thus, suggesting the therapeutic potential of lipidlowering medications such as lipase inhibitors and statins
(identiﬁed in our study) in AD and GIT disorders. Lipase inhibitors (orlistat) prevent intestinal dietary lipid absorption, and
lower total plasma triglycerides and cholesterol levels73,74, making
them a preferred pharmacological treatment for obesity73. The
connection between AD, lipid dysregulation, dysbiosis and the
‘gut-brain axis’10,66, may, thus, support the potential utility of
lipase inhibitors in AD. Lipases, including monoacylglycerol,
diacylglycerol, and lipoprotein lipases are involved in AD
pathology, and can also effectively be inhibited by orlistat74.
Similarly, statins possess anti-inﬂammatory, immune-modulating
and gastroprotective properties75,76, and their active use signiﬁcantly reduced PUD risk76 as well as enhanced H. pylori
eradication77. Statins also improve cognitive ability and reduce
neurodegeneration risks, making them potentially beneﬁcial in
AD78,79. However, there is evidence suggesting a paradoxical
predisposition to reversible dementia for statins78,79. While this
ﬁnding has been challenged78, it may highlight a need to identify
AD patients for whom statins will be beneﬁcial, consistent with
the model of personalised health.
Our ﬁndings have implications for practice and further studies.
First, results highlighting lipid-related mechanisms support the
roles of abnormal lipid proﬁles in the aetiologies of the disorders,
which may be potential biomarkers for AD and GIT disorders (or
their comorbidity). Second, our ﬁndings underscore the importance of lipid homoeostasis. The dietary approach is one effective
preventive as well as non-pharmacologic approach for the management of hyperlipidaemia, and overall, this is consistent with
ﬁndings in this study. Indeed, adherence to a ‘Mediterranean’ diet
(low in lipids) is recognised as beneﬁcial both in AD80 and GIT
disorders81. Thus, a recommendation for healthy diets, early in
life, may form part of the lifestyle modiﬁcations for preventing
AD and GIT disorders. The clinical utility of these recommendations will need to be further investigated and validated. Third,
our study identiﬁes lipase inhibitors and statin pathways in the
mechanisms of AD and GIT disorders, which may be a potential
therapeutic avenue to explore in the disorders. We hypothesise
that individuals with comorbid AD and GIT traits may gain
beneﬁts from these therapies. There is a need to test this
hypothesis using appropriate study designs including randomised
control trials. Fourth, our study implicates the PDE4B, and given
the evidence in the literature58–61, we propose that treatment
targeted at its inhibition may be promising in comorbid AD and
GIT traits. Lastly, while our ﬁndings do not necessarily indicate
that AD and GIT disorders will always co-occur, they support
their shared biology; thus, early detection of AD may beneﬁt from
probing impaired cognition in GIT disorders.
The use of multiple, complementary statistical genetic
approaches enables a comprehensive analysis of the genetic
associations between AD and GIT disorders and is a major
strength of this study. Also, we analysed well-powered GWAS
data, meaning our ﬁndings are generally not affected by small
sample size, possible reverse causality, or confounders that conventional observational studies often suffer from. Nonetheless,
our study has limitations that should be considered alongside the
present ﬁndings. First, the GWAS for AD combined clinically
diagnosed cases of AD with proxies (AD-by-proxy—individuals
whose parents were diagnosed with AD). Given the high
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correlation between the GWAS with and without the ‘AD-byproxy’ cases21, we argue as did others21 that combining them is
valid, especially for sample size improvement, which is critical to
ensuring adequately powered GWAS analysis. Second, analyses
were restricted to participants of mainly European ancestry in our
study, thus, ﬁndings may not be generalisable to other ancestries.
Third, GIT traits GWAS were combinations of several data
sources: primary care, hospital admission, medication use, and
self-reported records. While there is a potential for misdiagnosis
or accuracy of self-reported data, their use is well justiﬁed given
the correlation in effect sizes of the data with other sources22.
Moreover, additional data from other sources including ICD-10
were utilised with consistent results across these GWAS.
In conclusion, this study provides genetic insights into the
long-standing debate and the observed relationship of AD with
GIT disorders, implicating shared genetic susceptibility. Our
ﬁndings support a signiﬁcant risk increasing (but non-causal)
genetic association between AD and GIT traits (GERD, PUD,
PGM, gastritis-duodenitis, IBS, and diverticular disease). Also, we
identiﬁed genomic regions and genes, shared by AD and GIT
disorders that may potentially be targeted for further investigation, particularly, the PDE4B gene (or its subtypes) which has
shown promise in inﬂammatory diseases57–60. Our study also
underscores the importance of lipid homoeostasis and the
potential relevance of statins and lipase inhibitors in AD, GIT
disorders or their comorbidity. To our knowledge, this is the ﬁrst
comprehensive study to assess these relationships using statistical
genetic approaches. Overall, these ﬁndings advance our understanding of the genetic architecture of AD, GIT disorders, and
their observed co-occurring relationship.
Methods
GWAS summary statistics. The GWAS data utilised in the present study are
summarised in Table 1 with further cohort-speciﬁc details, including effective
sample size estimates, provided in Supplementary Data 1. The data were sourced
from popular GWAS databases, repositories, and large research consortia/groups.
The GWAS summary data for ‘clinically diagnosed AD and AD-by-proxy’21 (the
largest publicly available AD GWAS) was used as our AD GWAS data. This GWAS
has large sample size (cases = 71,880, controls = 383,378, sample size
[N] = 455,258) and, thus, increased power for detecting genetic variants of small to
moderate effect sizes. More speciﬁc details about the data have been published21.
GIT traits including PUD (cases = 16,666, controls = 439,661, N = 456,327), IBS
(cases = 28,518, controls = 426,803, N = 455,321), and IBD (cases = 7045, controls
= 449,282, N = 456,327) were assessed against AD. The GWAS for the traits were
obtained from the recently published GIT GWAS22 and other sources located
through the GWAS Atlas24 (Supplementary Data 1). Clinically, PUD medications
are indicated in GERD and gastritis, accordingly, GWAS combining diagnosis for
PUD and/or GERD and/or medications commonly used for these disorders (PGM)
have been conducted22, potentially identifying people with PUD or GERD. This
GWAS has a large sample size (cases = 90,175, controls = 366,152, N = 456,327),
and as was the case in the original publication22, we utilised the data for analysis in
the present study, as a proxy for PUD or GERD. These GIT GWAS were well
characterised and, where possible, validated as described in the original
publication22.
Additionally, we utilised a well-characterised GWAS for GERD (cases = 71,522,
controls = 261,079, N = 332,601), which combined data sets from the UK Biobank
and the QSKIN study23. Gastritis-duodenitis (cases = 28,941, controls = 378,124,
N = 407,065) and diverticular disease (cases = 27,311, controls = 334,783,
N = 362,094) GWAS from the Lee Lab (https://www.leelabsg.org/resources) were
also used in this study. We utilised additional (available) GWAS summary data
(Table 1 and Supplementary Data 1) sourced from public repositories used for
possible replication of our genetic overlap and correlation (LDSC and SECA)
ﬁndings. A comprehensive description of the quality control procedures for each of
the GWAS data and their analysis are available through the corresponding
publications (Table 1 and Supplementary Data 1). Our preliminary analysis
indicates that there is no signiﬁcant sample overlap between the AD GWAS and
each of the GIT GWAS assessed in this study (Supplementary Data 2), ruling out
the possibility of bias from such occurrence.
Linkage disequilibrium score regression analysis (LDSC). We assessed and
quantiﬁed SNP-level genetic correlation between AD and GIT disorders using the
LDSC25 analysis method (https://github.com/bulik/ldsc/wiki/Heritability-andGenetic-Correlation). LDSC assesses and distinguishes the contributions of
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polygenicity, sample overlaps, and population stratiﬁcation to the heritability and
genetic correlation between traits25. In the present study, we performed LDSC
analysis using the standalone version of the software and by following the procedures provided by the program developer (https://github.com/bulik/ldsc). The
apolipoprotein E (APOE) region has a large effect on the risk of AD; hence, we
excluded APOE and the 500 kilobase (kb) ﬂanking region (hg19,
19:44,909,039–45,912,650) from the AD GWAS for this analysis. We also excluded
SNPs in the 26–36 megabase region of chromosome six from the data given the
complex LD structure in the human major histocompatibility complex (MHC). To
assess possible sample overlap between AD GWAS and each of the GIT GWAS, we
performed LDSC correlation analysis with the genetic covariance intercept
unconstrained. The result of this analysis indicates that the estimated genetic
covariance intercepts were not signiﬁcantly different from zero (Supplementary
Data 2), indicating no signiﬁcant sample overlap between our AD and GIT GWAS.
Thus, we constrained the intercept in the reported genetic correlation analysis. We
applied Bonferroni adjustment for testing the effects of seven GIT traits on AD
(0.05/7 = 7.1 × 10−3), and all genetic correlation results surviving this adjustment
were considered signiﬁcant while those having P < 0.05 were regarded as nominally
signiﬁcant.
SNP effect concordance analysis (SECA). We used the standalone version of the
SECA software pipeline to perform SNP-level genetic overlap assessment and
statistical tests between AD and GIT disorders. A detailed description of the SECA
software and methods has been published26. Brieﬂy, SECA accepts a pair of GWAS
data (data set 1 and data set 2) as input and performs a range of analyses to assess
concordance in effect direction between a pair of traits—AD and GIT disorders in
the present study. First, we carried out quality control to exclude all non-rsID(s)
and duplicate variants in data set 1 and align SNP effects to the same effect allele
across data set 1 and data set 2. Second we performed two rounds of P-value
informed LD clumping in data set 1 (ﬁrst clumping: -clump-r2 0.1, -clump-kb
1000; second clumping: -clump-r2 0.1, -clump-kb 10000) using PLINK 1.9030.
Third, SECA partitions independent SNPs resulting from LD clumping into
12 subsets of SNPs according to the P value for data set 1 as follows: P1 ≤ (0.01,
0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0). SECA subsequently performs
Fisher’s exact tests to assess the presence of excess SNPs in which the direction of
effects is concordant across data set 1 and data set 2 (that is, for the corresponding
P value derived 12 subsets of SNPs associated in data set 2, P2). Hence, a total of
144 SNP subsets (a 12 by 12 matrix from data set 1 and data set 2) were assessed for
SNP effect concordance. SECA calculates permuted P value for the number of
signiﬁcant associations with adjustment for testing 144 associations (based on
permutations of 1000 replicates).
In the present study, we ﬁrst assessed AD GWAS as data set 1 and each of the
GIT disorders as data set 2. For comparison, we also assessed each of the GIT
disorders as data set 1 against AD as data set 2. Thus, using SECA, we assessed the
effects of AD-associated SNPs on each of the GIT disorders and vice versa. Since
SECA is conditioned on data set 1, the bi-directional assessment is an important
analysis step to account for instances where SNPs that are strongly associated with
AD do not affect GIT traits and vice versa. Further, the bi-directional analysis
(which is not possible with LDSC, for example) enables the assessment of whether
the observed genetic overlap is driven primarily by only one of the traits or both
thereby enhancing a better understanding of their association.
GWAS cross-traits meta-analysis. GWAS meta-analysis pools the results of
GWAS data, thereby increasing the sample sizes and augmenting the detection of
genetic variants with small to moderate effect sizes. In the present study, we used
the GWAS meta-analysis method of pooling AD GWAS with each of the GIT traits
(cross-disorder or cross-trait meta-analysis). We used two models of meta-analysis:
the Fixed Effect (FE), and the modiﬁed Random Effect (RE2)82 models. The FE
model estimates the FE P-value using the inverse‐variance weighted method, which
assumes that the AD and each of the GIT disorders’ GWAS are assessing the same
(ﬁxed) effect. The presence of effect heterogeneity is a limitation of the model. On
the other hand, by estimating P-values using the modiﬁed random effects, the RE2
model82 allows for differences in SNP effects and the method is powerful in the
presence of SNP effect heterogeneity.
Genomic loci characterisation. Using the outputs of our cross-trait meta-analyses
for AD and each of the GIT disorders, we carried out some downstream analyses
including functional annotation of SNPs, and genomic loci characterisation in line
with practice in the previous studies13,55,83,84. Brieﬂy, SNPs that were not genomewide signiﬁcant in the individual AD and GIT disorder GWAS, but which reached
genome-wide signiﬁcance following the meta-analysis were identiﬁed. From these,
we characterised independent SNPs at r2 < 0.6, and lead SNPs at r2 < 0.1. We
deﬁned the genomic locus as the region within 250 kb of each lead SNP. We
assigned lead SNPs within this region to the same locus, meaning two or more lead
SNPs may be present in one locus. We performed these downstream analyses using
the Functional Mapping and Annotation (FUMA) software (an online platform)55.
We subsequently queried identiﬁed loci in the GWAS catalogue (https://www.ebi.
ac.uk/gwas) and Open Targets Genetics (https://genetics.opentargets.org) to assess
their previous identiﬁcation for AD, GIT disorders or other traits.
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Pairwise GWAS analysis. We performed a co-localisation analysis utilising the
pairwise GWAS (GWAS-PW) method27 to further assess the regions in the genome shared by AD and GIT disorders. Brieﬂy, GWAS-PW software implements
the Bayesian pleiotropy association test and identiﬁes genomic regions that inﬂuence a pair of correlated traits27. We used this method to assess whether the loci
reaching genome-wide signiﬁcance in our GWAS meta-analyses were truly shared
by AD and the GIT disorders. Also, we investigated other shared genomic regions
which may not have been found in the GWAS meta-analysis. We combined the
summary data for AD with the data for each of the GIT disorders and estimated
the posterior probability of association (PPA) of a genomic region using the
GWAS-PW software. We modelled four PPAs: (i) that a genomic region is associated with AD only (PPA-1), (ii) that a genomic region is associated with the GIT
trait only (PPA-2), (iii) that a genomic region is associated with both AD and the
GIT trait and the causal variant is the same (PPA-3), and (iv) that a speciﬁc
genomic region is associated with both AD and the GIT trait but through separate
causal variants (PPA-4)27.
Causal relationship assessment. Using MR28 analysis methods, we assessed the
causal association between AD and each of the GIT disorders in this study.
Mimicking randomised control trials (RCTs), MR analysis incorporates genetics
into epidemiological study designs to assess causality28. The method is based on the
principle of instrumental variables and underpinned by three primary assumptions.
First is the relevance assumption which requires that the chosen instruments are
robustly associated with the exposure variable85. Second is the independence
assumption which states that the instruments must not be associated with confounders of the exposure-outcome variables85. Last is the assumption of exclusion
which demands that the instruments inﬂuence the outcome only through their
relationship with the exposure variable85.
In the present study, we used the two-sample MR method (https://mrcieu.
github.io/TwoSampleMR/articles/introduction.html) for a bidirectional association
assessment between AD and each of the GIT disorders. In the ﬁrst round of
analysis (AD as exposure variable), independent (r2 < 0.001) genome-wide
signiﬁcant SNPs (P < 5 × 10−8) associated with AD were utilised as instrumental
variables (IVs) and assessed against each of the GIT disorders’ GWAS (outcome
variables) analysed in this study. This analysis assesses whether genetic
predisposition to AD is causally associated with any of the GIT traits included in
the present study. Reversing the direction of analysis, independent SNPs robustly
associated with each of the GIT disorders’ GWAS (exposure variables) were
similarly utilised as IVs and assessed against AD (as the outcome variable). In this
instance, we assessed the potential causal effects of GIT traits on AD.
We used the inverse variance weighted (IVW) model of MR as the primary
method for causal association assessment, and for validity testing, we performed a
heterogeneity test (Cochran’s Q-test), a ‘leave-one-out’ analysis, a horizontal
pleiotropy check (MR-Egger intercept) and individual SNP MR analyses. Also, we
used other MR analysis models including the MR-Egger, weighted median86,87, and
the ‘Mendelian randomisation pleiotropy residual sum and outlier’ (MR-PRESSO)88
methods for sensitivity testing. The MR-Egger and weighted median models operate
under weaker assumptions of MR and are designed to provide valid causal estimates
even when horizontal pleiotropy is present in all (MR-Egger) or as much as 50%
(weighted median) of selected IVs86,87. Conversely, the MR-PRESSO method can
detect and correct horizontal pleiotropy by excluding outlier IVs thereby improving
valid causal estimates88. All MR analyses were performed in R (4.0.2).
We performed an additional assessment of the causal or partial causal
association between AD and each of the GIT disorders using the Latent Causal
Variable (LCV) method29. LCV estimates causality proportion (GCP) ranging from
−1 to 1 where a value close to 1 indicates a potential causal association between
two traits in the forward direction and −1 in the backward direction29. LCV
corrects for heritability and genetic correlation between traits and is not limited by
sample overlap29. This analysis was performed in the online platform of the
Genetics of Complex Traits (CTG) virtual laboratory (https://vl.genoma.io/
analyses/lcv)29,89.

Gene-based association analysis. We performed gene-based association analyses
to identify genome-wide signiﬁcant genes shared by both AD and each of the GIT
disorders assessed in this study. This analysis complements the SNP-based studies.
However, beyond the SNP level, gene-based association analysis provides greater
power for identifying genetic risk variants since it aggregates the effects of multiple
SNPs, and it is generally not limited by small effect sizes or correlations among
SNPs. Moreover, genes are more closely related to biology than SNPs, meaning
gene-level analysis can provide better insights into the underlying biological
mechanisms of complex traits.
In the present study, we carried out gene-based association analysis separately
for AD and GERD using the multi-marker analysis of genomic
annotation (MAGMA) software, implemented in the FUMA (https://fuma.ctglab.
nl/)55 platform. We deﬁned gene boundaries length within ±0 kb outside the gene,
and to ensure that equivalent gene-based tests were performed, we utilised SNPs
overlapping AD and GERD GWAS in analysis separately for each of the traits.
Following a similar procedure, we also performed gene-based analysis using SNPs
overlapping AD and PGM GWAS.
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Based on the results of the gene-based analysis, we identiﬁed genome-wide
signiﬁcant genes for each of the traits—AD, GERD and PGM—at an adjusted P
value of 2.64 × 10−6 (0.05/18929: Bonferroni adjustment for testing 18,929 genes).
Further, to identify genes shared by AD and each of GERD and PGM, we extracted
their overlapping genes at gene P value <0.1 (Pgene < 0.1). We combined the
respective P values for AD and the GIT traits using Fisher’s Combined P-value
(FCP) method and thereafter identiﬁed shared genes reaching genome-wide
signiﬁcance for AD and each of GERD and PGM in the FCP analyses.
Pathway-based functional enrichment analysis. For a better understanding of
the potential biological mechanisms underlying AD and GIT disorders or their
comorbidity, we carried out pathway-based functional enrichment analyses using
the online platform of the g:GOst tool in the g-proﬁler software56. The g:GOst tool
performs analysis on the list of user-inputted genes and queries relevant databases
including Gene Ontology, Human Protein Atlas, WikiPathway, Human Phenotype
Ontology, CORUM, Kyoto Encyclopedia of Genes (KEGG), and Reactome. This
analysis enables us to functionally interpret genes overlapping AD and GIT disorders. We included genes that were overlapping between AD and each of GERD
and PGM at Pgene < 0.05 (FCP < 0.02) in this analysis, and followed established
protocols90. Functional category term sizes were restricted to values from 5 to
35090. For multiple testing corrections, we applied the default ‘g: SCS algorithm’
recommended in the protocol90 and reported the signiﬁcantly enriched biological
pathways at the multiple testing adjusted P value [Padjusted] < 0.05.
Statistics and reproducibility. We performed statistical analysis mainly in the
Unix environment and the R (https://www.r-project.org/) software. Additional
software including Python (https://www.python.org/), Plink (https://www.coggenomics.org/plink/) and online platforms (CTG virtual lab: https://vl.genoma.io/
updates, G-proﬁler: https://biit.cs.ut.ee/gproﬁler, and FUMA: https://fuma.ctglab.
nl) were utilised. Adjustment for multiple testing was carried out using the Bonferroni approach in LDSC, gene-based and meta-analyses. In G-proﬁler, we applied
the recommended inbuilt ‘g: SCS algorithm’ for multiple testing corrections. To
enable us to test the reproducibility of AD and GIT association, we used available
GIT data for further analysis.
Ethics approval and consent to participate. This study is a secondary analysis of
existing GWAS summary data from public repositories, and international research
consortia. Speciﬁc and relevant ethics approval for each of the data utilised is
presented in the associated publications described in the section for GWAS summary data. No additional ethics approval is required for the conduct of the
present study.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data generated during this study are included in the published article and its
Supplementary section. GWAS summary statistics data analysed were sourced from
international research consortia and public repositories as described in the subsection for
GWAS summary data. The data are freely available and accessible online through the
links and references provided within this study. Supplementary Data 1 provides a
comprehensive description of the data and how to access them.

Code availability
We used publicly available software for analysis in this study. Here, we list the URLs
(some of which are online methods) for the software where details about them including
(where applicable) the computer codes are available: CTG virtual lab (https://vl.genoma.
io/updates), FUMA (https://fuma.ctglab.nl/), G-proﬁler (https://biit.cs.ut.ee/gproﬁler/),
GWAS Catalogue (https://www.ebi.ac.uk/gwas/home), GWAS-PW (https://github.com/
joepickrell/gwas-pw), LDSC (https://github.com/bulik/ldsc), SECA (https://sites.google.
com/site/qutsgel/software?authuser=0), Open Target Genetics (https://genetics.
opentargets.org/), and Two-Sample MR (https://mrcieu.github.io/TwoSampleMR/
articles/introduction.html).
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